OPKO Health, Inc. (OPK)
Healthcare
- Fundamental
- 2
- Sentiment
- 3
- Technical
- 3
Do Nothing: fundamentalScore is 2 (below the required floor of 3), so the strategy cannot open a bullish entry regardless of the intact uptrend chart; both the pullback-limit posture (price above SMA50/SMA200 with MACD >= 0) and the breakout-stop alternative above the 1.74-1.75 shelf are left unsized because the trade plan is skipped under the fundamental hard block.
Company overview
OPKO Health, Inc. is a healthcare company focused on diagnostics and pharmaceuticals, operating in the U.S. and internationally. Its Diagnostics division includes BioReference Laboratories, offering comprehensive laboratory testing services. The Pharmaceutical segment develops and markets therapeutic products, with a focus on proprietary, extended-release versions of existing therapeutic proteins.
Fundamental
weakOPKO Health's fundamentals are weak, with consistent losses, negative cash flow, and high financial risk.
Cash-rich but structurally loss-making. Five consecutive unprofitable years, revenue down roughly two-thirds from 2021, negative EBITDA and negative free cash flow, an Altman Z-Score deep in the distress zone, and discounted-cash-flow values far below the $1.68 share price. Supported by $390.2M of cash, modest net debt of $123.9M, no going-concern doubt, no covenant issues, and a signed $722.0M cash sale of BioReference to Labcorp that would flip the balance sheet to net cash when it closes. Elevated risks include a roughly $246M Israeli tax assessment, a ~12% secured royalty financing with punitive make-whole terms, and an R&D segment that consumed $84.9M in nine months. Weak fundamentals, high risk, wait for execution.
Sentiment
fairSentiment is mixed, with positive media coverage on the Labcorp deal but no immediate catalysts.
Dominant catalyst is the unresolved Labcorp/BioReference asset sale ($722.0M cash plus up to $150.0M earnout, signed 2026-10-14, announced-confidence ongoing_process) — genuinely market-rewarded at announcement but now trailing and only partially priced, with no disclosed close date inside the 30-day horizon. Sentiment delta is flat (aggregate media polarity +0.23 baseline to +0.19 scoring), the 2026-11-04 Q3 revenue miss with a $53.5M GAAP net loss keeps the tape mixed, retail is indeterminate (Reddit access blocked), and the Red-Flag Screen is clean so no cap applies.
Technical
fairThe stock is consolidating above key moving averages, but momentum has cooled.
Uptrend intact but short-term momentum has cooled. OPK at 1.68 sits above a rising SMA20 (1.674), SMA50 (1.602) and SMA200 (1.364), but just below EMA9 (1.694) and beneath DEMA14 (1.721) / TEMA14 (1.715), with RSI 54.6 and Williams %R -66.7 - a mid-range consolidation after the 2026-11-06 spike high of 1.86, not a fresh thrust. ADX 30.2 confirms a strong but decelerating trend (down from 35.4 two weeks ago) while MACD has flattened onto its signal (line 0.04, histogram 0.00). ATR14 0.08 (4.76% of price) leaves room for an ATR-scaled target and 20-day dollar volume of $5.84M clears the liquidity floor, though the last three regular sessions have run lighter (~$3.63M). Chart quality is a legitimate pullback-to-support-looking consolidation, but the trade is blocked at the pre-flight gate: fundamentalScore 2 is below the required floor of 3, so no plan is sized.
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

